This Live Talk is produced by Being Patient with support provided by Cognito Therapeutics. Learn more about Cognito's HOPE Study:https://www.hopestudyforad.com/ – Researchers and technology companies are looking into whether non-invasive, non-drug therapies — like electromagnetic, visual, and auditory stimulation — can treat Alzheimer’s disease. So, what does the science say about these emerging therapies? What can they do for the brain?Dr. Michelle Papka, founder and president of the Cognitive and Research Center of New Jersey (CRCNJ), joined Being Patient Live Talks to discuss emerging technology-assisted non-invasive interventions for Alzheimer’s. Papka is a neuropsychologist, psychotherapist, and researcher with more than 30 years of combined experience working in aging, Alzheimer’s, and dementia, and her own private clinical practice in New Jersey. She’s also an active public speaker, invited editor, grant reviewer, consultant, and committee member of multiple specialized organizations and publications on aging and Alzheimer’s.For over 15 years, she has served as the principal investigator on industry-sponsored clinical trials for Alzheimer’s disease and age-related cognitive impairment. Presently, she’s the principal investigator on Cognito’s HOPE study, which is testing the SPECTRIS AD device’s efficacy and safety for people living with Alzheimer’s, and an advisor to Cognito. This device uses visual and auditory stimulation to create gamma wave activity in the brain. Listen to the live talk to learn her perspective on non-invasive interventions for Alzheimer’s disease and what the future may hold for these treatments.

Ask this episode

“What did the council decide on item 42?” — answered with the speaker and the moment.

Transcript

Related